公开(公告)号：US20240092918A1

公开(公告)日：2024-03-21

申请号：US18164519

申请日：2023-02-03

Applicant: Novartis AG

Inventor： Steven BENDER ,  Tracy CHARLTON ,  Anna GALKIN ,  Bernhard Hubert GEIERSTANGER ,  Scott Martin GLASER ,  Shailaja KASIBHATLA ,  Mark KNUTH ,  Sabine ROTTMANN ,  Sarah RUE ,  Glen SPRAGGON ,  Tetsuo UNO

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  A61K2039/505

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20210228731A1

公开(公告)日：2021-07-29

申请号：US17253584

申请日：2019-06-19

Applicant: NOVARTIS AG

Inventor： Anthony Edward BOITANO ,  Matthew T. BURGER ,  Susan E. CELLITTI ,  Michael Paul COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Si-Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO ,  Yongqin WAN ,  Ben WEN ,  Qiang ZHANG

IPC: A61K47/68 ,  C07K16/28 ,  A61K38/07

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20190382441A1

公开(公告)日：2019-12-19

申请号：US16439204

申请日：2019-06-12

Applicant: NOVARTIS AG

Inventor： Bernhard Hubert GEIERSTANGER ,  Jan GRUNEWALD ,  Yunho JIN ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Xing WANG

IPC: C07K5/02 ,  A61K47/68 ,  C07K7/02 ,  C07K16/32

Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

公开(公告)号：US20210346387A1

公开(公告)日：2021-11-11

申请号：US17181896

申请日：2021-02-22

Applicant: NOVARTIS AG

Inventor： Alex CORTEZ ,  Bernhard Hubert GEIERSTANGER ,  Timothy Z. HOFFMAN ,  Shailaja KASIBHATLA ,  Tetsuo UNO ,  Xing WANG ,  Tom Yao-Hsiang WU

IPC: A61K31/52 ,  A61K47/68 ,  C07D487/04 ,  C07H15/26 ,  C07K16/28 ,  C07K16/32

Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

公开(公告)号：US20190321483A1

公开(公告)日：2019-10-24

申请号：US16470897

申请日：2017-12-19

Applicant: NOVARTIS AG

Inventor： Ben WEN ,  Anthony E. BOITANO ,  Matthew BURGER ,  Susan E. CELLITTI ,  Michael P. COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Yunho JIN ,  Si Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO

IPC: A61K47/68 ,  C07K16/28 ,  A61K38/07 ,  A61K38/12

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20220305134A1

公开(公告)日：2022-09-29

申请号：US17833077

申请日：2022-06-06

Applicant: Novartis AG

Inventor： Anthony Edward BOITANO ,  Matthew BURGER ,  Susan E. CELLITTI ,  Michael P. COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Yunho JIN ,  Si Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO ,  Ben WEN

IPC: A61K47/68 ,  A61K38/07 ,  A61K38/12 ,  C07K16/28

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20210170043A1

公开(公告)日：2021-06-10

申请号：US16669291

申请日：2019-10-30

Applicant: NOVARTIS AG ,  ADURO BIOTECH, INC.

Inventor： Lisa BARNETT ,  Steven BENDER ,  Charles Y. CHO ,  Sarah COX ,  Jonathan Deane ,  Scott Martin GLASER ,  Xueshi Hao ,  Shailaja KASIBHATLA ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Ben WEN ,  Tom Yao-Hsiang WU

IPC: A61K47/68 ,  C07K16/28 ,  A61K31/688 ,  A61P35/00

Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

公开(公告)号：US20200216548A1

公开(公告)日：2020-07-09

申请号：US16482173

申请日：2018-02-01

Applicant: NOVARTIS AG

Inventor： Steven BENDER ,  Tracy CHARLTON ,  Anna GALKIN ,  Bernhard Hubert GEIERSTANGER ,  Scott Martin GLASER ,  Shailaja KASIBHATLA ,  Mark KNUTH ,  Sabine ROTTMANN ,  Sarah RUE ,  Glen SPRAGGON ,  Tetsuo UNO

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20180244717A1

公开(公告)日：2018-08-30

申请号：US15961531

申请日：2018-04-24

Applicant: NOVARTIS AG

Inventor： Bernhard Hubert GEIERSTANGER ,  Jan GRUNEWALD ,  Yunho JIN ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Xing WANG

IPC: C07K5/02 ,  C07K7/02 ,  A61K47/68 ,  C07K16/32

CPC classification number: C07K5/0205 ,  A61K47/6817 ,  A61K47/6851 ,  C07K7/02 ,  C07K16/32

Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.